Pfizer settles Rezulin product liability litigation
Executive Summary
Pfizer has settled thousands of personal injury claims alleging the diabetes drug Rezulin (troglitazone) caused liver damage. The number of claims and the size of the settlement are confidential. However, Bloomberg reported that the company is paying $750 million to settle 35,000 claims. The company had set aside $975 million in 2003 for the litigation. Pfizer said the multidistrict litigation is now resolved and there are only a handful of cases remaining in state court, which it expects will be dismissed. Pfizer withdrew Rezulin from the market in 2000 after people taking the drug experienced liver failure